Genmab — November 2022
-
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update https://investors.biontech.de/news-releases/news-release-details/biontech-announces-third-quarter-2022-financial-results-and - Presentation - https://investors.biontech.de/static-files/49e8b81b-bc33-4d65-85ea-c935610dd6b2
-
Genmab sammen med Bava, har ingen omsætning i dag, så det er nok Hr. og Fru. Jensen der styrer markedet med de små handler.
-
Esmo abstract Dec 1. At 00.05 https://www.esmo.org/meeting-calendar/esmo-immuno-oncology-congress-2022/abstract
-
-
Forhandling og aftalefrihed. En milestone ved ansøgning viser umiddelbart, at Genmab har stået med stærke Epco-kort på hånden i forhandling med de potentielle partnere tilbage i 2019/20.
-
Agree. It is a bit unusual to see such front loaded agreement "upon submission". It may reflect that Genmab brought Epco most of the way on its own and took some heavy RD on that path.
-
Som jeg husker det, så faldt aktien tilbage efter den ramte ATH. Er det kun Genmab det skete for eller er andre aktier også faldet tilbage efter en "kurstop".....
-
Det kan være der kommer et nyt gæt på, hvor kursen ikke er om 5-6 måneder. Så kan vi more os over det, når Epco måske bliver godkendt i forsommeren.
-
https://seekingalpha.com/article/4554273-biontech-se-bntx-q3-2022-earnings-call-transcript BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind